
    
      This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to
      evaluate the efficacy, safety, and tolerability of oral Nefecon compared to matching placebo
      in patients with primary IgAN on a background of optimized RAS inhibitor therapy. The study
      will consist of 2 parts, Part A and Part B. Part A will include a 9 month blinded Treatment
      Period, and a 3-month Follow up Period. Part B of the study will consist of a 12-month
      observational Follow up Period; no study drug will be administered during Part B. Part A and
      B will be blinded. Safety will be monitored by an independent Data Safety Monitoring Board.
    
  